An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study to Compare the Bioavailability of Two IMP4297 Formulations (20 mg Capsules and 10 mg Capsules) After Single Oral Administration of 100 mg IMP4297 Under Fasted Condition in Healthy Male Subjects
Latest Information Update: 25 Aug 2021
At a glance
- Drugs Senaparib (Primary)
- Indications Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors IMPACT Therapeutics
Most Recent Events
- 21 Aug 2021 Status changed from active, no longer recruiting to completed.
- 22 Nov 2020 Planned End Date changed from 1 May 2021 to 1 Jun 2021.
- 22 Nov 2020 Status changed from recruiting to active, no longer recruiting.